Therapeutic preparation 'aqueous-alcoholic solution of purified mumiyo'

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to therapeutic preparations of mumiyo. The therapeutic preparation which contains purified mumiyo, grapefruit citrosept, edible glycerol, ethanol and water at specific proportions.

EFFECT: preparation has a prolonged shelf life.

8 tbl

 

The invention relates to pharmaceutical industry, in particular to drugs mummy in the form of a solution.

Known biologically active additive "Manivit" in the form of tablets, comprising, by wt.%: mummy cleaned 25-30, starch 10-15, calcium stearate 5-10, sugar else. The necessity of introduction of inert additives are caused by specific physical and mechanical properties of Shilajit, namely high adhesive properties and high viscosity, and therefore tableting pure Shilajit is almost impossible, while the input of inert additives reduces quality of product (RF patent No. 2238100, IPC AC 35/78, AK 9/20, A23L 1/30, publ. 2004.10.20).

A well-known drug that has anti-inflammatory and antimicrobial action on the basis of Shilajit and ascorbic acid in the presence of the drug (to ensure process tabletting) talc, starch, calcium stearate and sugar, providing time raspadaemosti and pressing (talc, starch), improving the fluidity of the granular and increasing the strength of pressing (calcium stearate), as filler - sugar (RF patent No. 2174840, IPC AC 35/02, AK 9/06, publ. 200.10.20).

Known drug Shilajit powder, which Shilajit-extract injected powdered cellulose in the ratio 2:1, with Shilajit-extract transforms from a sticky mass in the bulk is Orasac, disappears stickiness, viscosity and moisture permeability. The drug in this form is the active ingredient in the composition of ointments, suppositories, tablets, etc. (RF patent No. 2068264, IPC AC 35/00 publ. 1996.10.27).

As can be seen from the above analogues, the tabletting process due to the high viscosity and high adhesive properties Shilajit without inert additives practically impossible, and the storage of such tablets when humidity over 50% of the drug gets some fluidity, tablets stick to the packaging, losing up to 20% by weight when removing that violates the dosage if it is applied.

Known liquid form SUPPLEMENTS water-based, contains Shilajit products shell pine nuts, chopped up melkodisperstnoy state cysts of Artemia salina and water in the following ratio of ingredients, wt.: Shilajit 1-20, food processing shell pine nut 1-20, cysts of Artemia salina 1-20, water the rest (RF patent No. 2345572, publ. 10.02.2009 - prototype). However, the presence in the aqueous solution of this drug such ingredient as the cyst Artemia salina, a small shelf life of the drug due to the fact that any protein compounds can only be stored either in limitirovannoe (subjected to freeze drying)or in canned form, because the protein in the presence of water is subject to natural decay.

Thus, at the present time in pharmacological practice making preparations Shilajit is no easy to prepare and usage dosage form of the drug long-term preservation of quality indicators mummy. In aqueous solution the product can be made with only 1-2 times use during the day, because the shelf life of aqueous solutions mummy short. Table 1 shows the research shelf life of aqueous solutions mumie different concentrations.

Table 1
The concentration of the aqueous solution mummy, %The retention time of the aqueous solution mummy, days
50,5
101,0
302,0

As can be seen from table 1, the shelf life of aqueous solutions mummy though and increases with increasing concentration of the solution in the solution, but even at a relatively high concentration dosage form is disposable.

With regard to the use of tablets mummy, inter alia, the manufacturers of the drug during its implementation encountered Thu the delivery and implementation of tablet forms of Shilajit in regions with high humidity and especially at high temperatures proved to be virtually impossible, as tablets under these conditions (despite the tight packing) lose their marketability and consumer properties (in the process of dissolving and stick to the package).

The objective of the invention is to develop a simple low-cost and technologically in the manufacture of dosage forms of Shilajit, easy to use, with a long shelf life, ensuring the high quality of the drug and the dosing accuracy when using.

This technical result is achieved by the fact that therapeutic drug on the basis of Shilajit is made in the form of a solution and contains purified Shilajit, ethyl alcohol, glycerin food, citrosa grapefruit, water in the following ratio, wt.%:

Shilajit is cleared25-30
ethyl alcohol18-22
glycerin food8-10
citracal1-6
waterrest

The invention consists in the following. As you know, mummy is poorly soluble in alcohol, at the same time alcohol as a good preservative may extend the shelf life wysokosc zentrierung solution mummy. However, high concentration may cause denaturation of the protein part of the mummy, reducing the quality of the product. In addition, the high content of alcohol in drug contraindicated adults who do not tolerate alcohol, and children. In the claimed invention proposed composition of ingredients in combination with Shilajit high concentrations, it provides a good solubility, a slight alcohol content in the solution, long term storage at high level of preventive and curative qualities of the drug.

Targeted supplements Shilajit (citrosa, glycerin, alcohol) are not inert components of the solution. The proposed combination of components, each of them makes a positive component in the solution of the problem, providing together a multifunctional effect.

Shilajit is a complex, multi-component combination of organic compounds and their mineralogical, among which more than 50 of macro - and microelements, essential oils, vitamins, organic, including humic acids, carbohydrates, albumin, amino acids, including glycine, wax-like and retinoid substances, gums, alkaloids, polyphenols, fatty acids, phospholipids and other substances. Shilajit relates to nonspecific immunostimuliruuchego actions, C is a powerful biostimulant, about 3.5 times more efficient taiga ginseng, with a broader range of biological actions. The trace elements contained in physiological proportions, have a favorable effect on the biochemical and physiological processes, metabolism, work enzyme systems, which contributes to resilience and adaptation. Due to the presence of high concentrations of minerals and trace elements Shilajit is an excellent antimicrobial, antiseptic. Shilajit is actively involved in the biosynthesis of DNA in the cell, therefore, has powerful healing properties and stimulates hematopoiesis. Shilajit has antispasmodic and sedative effect, exhibits a pronounced anti-coagulants and anti-toxic effect, protects against radiation, radiation, poisons, has antioxidant properties. Shilajit stimulates all the functions of the liver, showing distinct choleretic effect, helps reduce cholesterol and blood sugar levels. Shilajit has antitumor activity, which is associated with its ability to enhance the adaptive properties and to improve immunity. Humic acid in the composition of Shilajit inhibit inflammation, reduce the reactivity of capillaries and regulate vascular permeability reducing exudation and swelling of tissues, reduce on reshenie, remove intoxication. Essential oils in Shilajit are analgesic, and included in the mumie biologically active substances increase local and General immunity. On the recommendation of Oriental medicine Shilajit is applied in surgical (broken bones, sprains, bruises, wounds, atrophic ulcers, hemorrhoids), therapeutic (acute and chronic gastritis, colitis, peptic ulcer disease, hepatitis, cholecystitis, anemia, hypotension), nervous (epilepsy, migraine, inflammation and paralysis of peripheral nerves, stuttering, diminished hearing), infectious, inflammatory and allergic (quinsy, stomatitis, otitis, bronchitis, rheumatism, bronchial asthma, endometritis, salpingitis, cystitis) diseases, poisoning of plant and animal poisons (insect bites, Scorpion), and chronic alcoholism.

Mumie on elemental and organic compounds non-toxic and refers to treatments of the 4th class of hazard, i.e. almost safe (according to the toxicology laboratory of the NGO "Carbolite", Novosibirsk, 1989). Applied in the form of powder, tablets or freshly prepared solutions, soluble in water and poorly soluble in alcohol. The most common dose of 0.1-0.3 g mumie.

Citrosa grapefruit (standard 33% grapefruit seed extract) is antiseptic plant origin and mo which should be used as a floral preservative with useful properties. Registration certificate №B. Manufacturer: Norway, company "Chintamani international speakers". Composition: extract bioflavonoids, grapefruit seed (33%) and vitamin C (4.9 g), glycerol palm and water. Compared with conventional alcohol - and iodine-containing antiseptics of citracal has a broader spectrum of effects on microorganisms (more than 800 strains of gram-positive and gram-negative bacteria, more than 100 species of fungi and yeast, some viruses). 100 ml of nitrosate contains 19,37 g of bioflavonoids (quercetin, hesperidin, naringin and other)that contribute to its antiseptic properties. Antifungal activity of standardized 33%grapefruit seed extract is based on the delay of the enzyme cytochrome P-450, and antibacterial and antiparasitic - on damage to the cytoplasmic membrane, cell wall and on the containment of synthesis of amino acids by microorganisms (in the absence of toxicity for living organisms). Citracal has a wide range of actions, good disinfectant properties and is effective even in low concentrations (0.7 percent). The drug is nontoxic, is biodegradable, does not cause addiction, dependence and does not destroy the microflora, blends well with other natural medicines. In combination with Shilajit enhances therapeutic properties of the drug and effective disinfectant properties can reduce the amount of alcohol in the solution.

In medical practice citracal applied (according to the instructions for use) for candidiasis and other fungal diseases of the skin, mucous membranes and nails, dermatitis, mixed fungal-bacterial infections of the skin and nail plates, diseases of the respiratory tract (sinusitis, flu, colds, sore throat, asthma, bronchitis, diseases of the oral cavity (stomatitis, gingivitis, periodontal disease), diseases of the gut (dysbiosis, gastritis, hepatitis, liver failure, acute poisoning, HIV, parasites, insect bites, wounds, cuts, burns, varicose veins and venous ulcers, female fungal and bacterial infections, etc. so citrosa goes well with mummy on therapeutic impact, enhances the antimicrobial activity of Shilajit and extends its range (due to antiviral and antifungal actions nitrosate).

Glycerin (in the presence of an aqueous solution mummy in preparation) contributes to the absorption of a drug because of its molecule, with its small size and having a high tool with water molecules (having a hydrated shell), contribute to the saturation of the cells of the medicinal component of the drug. Molecule structure of extracellular fluid and protects the cell from harmful ultra high osmotic the ski influences, strengthening the function of nutrients to maintain optimal osmotic pressure. Glycerin mixed with water and alcohol in all respects and is a thickener, and a solvent for many organic and inorganic substances.

To determine the optimal combination of ingredients in the product were carried out experimental studies of medications for expiration dates when the alcohol content of 16% to 28% and nitrosate from 1 to 10%. The contents of Shilajit in this case amounted to 25-30% (almost the maximum level of solubility) and 10% glycerol food. The research results are reflected in table 2.

Table 2
Alcohol content, %The content of nitrosate, %The shelf life, months
With nitrazepam at 30% of the content of the mummyWith nitrazepam at 25% of the content of the mummyWithout nitrosate at 30% of the content of the mummy
166the 9.79,13,5
184-6 to 12.1 and 12.411,9-12,15,5
202-412,2-12,6to 12.0 and 12.46,9
221-212,4-12,912,2-12,68,7
24---the 10.1
26---11,5
28---a 12.7

Table 2 shows the shelf life (from the whole array of combinations of ingredients) preparations with a period of 12.5+0.4 months. The shelf life of concentrated mummy in the solution due to the time of production, the formation of the party of drug delivery to the consumer (especially in remote areas), use, and other unforeseen circumstances. With the exception of the data of the experimental samples with 16%alcohol, in the presence in the preparation of pristerene 6% nitrosate expiration date amounted to 9.7 months of data and prototype drugs without incorporating citraratha, where necessary, the shelf life was achieved only at 28%alcohol content in the solution.

As can be seen from table 2, with increasing number of nitrosate in the product from 1 to 6% of the required amount of alcohol to maintain the desired shelf life is reduced. So without nitrosate to maintain a 12-month shelf life, you must have 28% alcohol, while the content in solution 1-2% of nitrosate ensures the shelf life is already at 22% alcohol, and 4-6% of nitrosate - at 18% alcohol in the product. The optimal combination of ingredients according to the task you should consider the following ratio, wt.%: Shilajit is cleared by THE 9197-002-01898825-05-25-30%, glycerol according to GOST of 6,824 10%, citrosa 1-6%alcohol according to GOST 51652 18-22%), water according to GOST R, SanPiN 2.1.4.1074-2001. Studies have shown that the qualitative indicators of the drug when the content of glycerin is from 8 to 10% were identical, which expanded input range of glycerol in the product.

Microbiological studies of the drug after 12 months of storage are presented in table 3.

Table 3
№ p/pDefined indicatorsThe results of the research unitVe is hichina acceptable level, unitsND on research methods
12345
1ClaphamLess than 1×102CFU/gNot more than 1×104CFU/gGOST 10444.15-94
2BGK (coliforms)1.0 g neobaroque1.0 g not detectedGOST 30518-97 (GOST R 50474-93)
3S.aureus1.0 g not detected1.0 g not allowedGOST 10444.2-93
4Pathogenic, including Salmonella1.0 g not detected1.0 g not allowedGOST 30518-97 (GOST R 50474-93)
5Yeasts, mouldsLess than 10 CFU/gNot more than 100 CFU/gGOST 10444.12-88
6 V.parahaemolyticusLess than 10 CFU/gNo more than 200 CFU/gMUK 4.2.1793-03

As can be seen from table 3, the preparation for microbiological indicators corresponds to SanPiN 2.3.2.1078-01 "Hygienic requirements for safety food nutrition" (ind 1.10.6.1).

The biological value of the product are presented in table 4.

Table 4
IndexMG in a daily dose (30 drops=1.5 ml)% of an adequate level of consumption per day
The content of humic acids16(16)*100
The content of flavonoids (in terms of luteolin)1,5-4,5(5)*30-90
The content of free organic acids (in terms of malic acid)6(500)*1.2
* adequate level of consumption per day for MU 2.3.2.1915-04

As can be seen from table 4, the daily dose of the claimed drug satisfies 100% of the daily need the TB organism in humic acids and 30-90% of the need for flavonoids.

Organoleptic and physico-chemical characteristics of the drug on the basis of Shilajit are given in table 5.

Table 5
Name of indicatorThe index of the drug on the basis of the mummy
AppearanceHomogeneous, thickish solution from dark brown to black color
TasteBitter-tart
SmellSpecific resinous with a light citrus scent
Density, g/cm3not less than1,1
pH of 1% aqueous solution7,5-7,9
The dry residue,%, not less than40,0
The content of free organic acids, % not less than0,4
The content of flavonoids (in terms of luteolin), % not less than0,1
The content of humic acid,%, not less than1,0
The content of total ash,%, not less than6,0
The content of ash insoluble in 10% hydrochloric acid,%, not less than0,3

Therapeutic drug on the basis of Shilajit is prepared as follows.

Example 1. 25 kg of crushed purified Shilajit load in an industrial mixer, add 42 liters of water. The operation of the mixer is continued until complete dissolution mummy within 3-4 hours. The resulting solution is pumped into copier with an agitator, there are introduced 2 kg of nitrosate grapefruit, 9 kg of glycerol food, 22 kg of ethyl alcohol. The mixture was thoroughly stirred for at least 30 minutes and filled into sterile glass vials (sterilized at a temperature of 140±5°C for 40 minutes) or in polypropylene vials (sterilization at 60±1°C for 3 hours) with lids-droppers, caps-pipettes.

Example 2. The sequence of technological operations were conducted as in example 1 with the following ratio of components: purified Shilajit - 30 kg, ethyl alcohol 18 kg, citrosa grapefruit 5 kg, glycerin food 10 kg, water 37 kg

Example 3. The process sequence of example 1 in the following ratio of components: purified Shilajit 27 kg, ethyl alcohol 20 kg, cytosep grapefruit 4 kg, glits the Rin food 10 kg, water 39 kg

Since 15 drops of preventive and curative medicine on the basis of Shilajit corresponds to the contents of Shilajit is one tablet weighing 0.2 g, most often used in medical practice, treatment and prevention of disease declared by the drug is similar to the existing practice of treatment. In the presence of bioflavonoids, which complement and enhance the properties of Shilajit, declared the drug is especially effective in infectious-inflammatory diseases of bacterial, fungal, viral etiology (candidiasis, dermatitis, infections of the genital organs, sore throat, respiratory infection, stomatitis, gastritis, colitis and other), metabolic disorders (diabetes mellitus, hypercholesterolemia, obesity and others), increased blood viscosity (diseases of the cardiovascular system, their complications, and others), vascular diseases (inflammation, atherosclerosis, varicose and others), dysbiosis, immune deficiency, prevention of secondary infections, after chemotherapy, radiation therapy and antibiotic therapy, etc.

The results of comparative trials for the treatment of several diseases tablets mummy by known techniques and claimed the drug is given in tables 6 and 7.

A clinical study was conducted on a group of probando aged 21-59 years (20 people) with diagnoses of chronic gastritis with different secretory AK is ewnetu, HP+, chronic colitis and thrombophlebitis of deep veins of lower extremities, table 6.

Table 6
DiseaseDosage and method of application by authorDosage and method of application of the claimed drugThe results of the application by authorThe results of applying the claimed drug
Chronic gastritis with different secretion of gastric juiceAn oral dose of 100 mg 3 times a day (morning, afternoon and evening) for 15-20 days, 30 minutes before meals with low, for 40-45 minutes before meals with normal and 1.5 h before meals with increased secretion of gastric juice. Askarov L.A, 1980.An oral dose of 15 drops 3 times a day (morning, afternoon and evening) for 21 days, 30 minutes before meals with low, for 40-45 minutes before meals with normal and 1.5 h before meals with increased secretion of gastric juice. Before use the preparation to pre-dissolve in a volume of 1 tablespoon of boiling water.Decrease pain in patients was observed at 4-6 days of treatment, and the complete disappearance of his, including local disease is con-9-12 day. All dyspeptic symptoms (nausea, vomiting, heartburn, belching and other) was held on 7-10 day treatment. Normalization of stool - 6-15 day of treatment.After 15-20 minutes after taking the drug, almost all patients had decreased or disappeared sense of pain, and the complete disappearance of his - 4-9 day. Pain to palpation disappeared for 9-12 days of treatment. All dyspeptic symptoms (nausea, vomiting, heartburn, belching and other) was held on 6-9 day of treatment. Normalization of a chair - in 5-12 days of treatment.
Chronic colitisAn oral dose of 200 mg 1 time a day for 10 days for 30 minutes before a meal. Abdurakhmanov TR, 1970.An oral dose of 15 drops 1 time per day for 10 days for 30 minutes before a meal. Before use, the drug preThe main symptoms of the disease disappeared for 5-10 days of treatment.Decrease in pain observed for 3-4 days of treatment, the disappearance of phenomena
dissolved in a volume of 1 tablespoon of boiling water.gastrointestinal dyspepsia, spasms - 8-9 day of treatment. Normalization of stools within 1-2 weeks.
The clot is phlebitis deep vein of lower limb An oral dose of 300 mg 1 time a day for 10 days for 30 minutes before a meal. Abdurakhmanov TR et al., 1970.An oral dose of 15 drops 1 time per day for 10 days for 30 minutes before a meal. Before use the preparation to pre-dissolve in a volume of 1 tablespoon of boiling water.Decrease feelings of pain, degree of swelling and the volume of the diseased limb - 3-6 days of treatment. 8-10 day normalized skin temperature, disappeared other symptoms.The reduction of pain, degree of swelling and the volume of the diseased limb - 2-4 days of treatment. 6-8 day of treatment normalized skin temperature, disappeared other symptoms.

Therapeutic drug on the basis of Shilajit can be used without special technological methods, in the production of medicines, as their basis. Replacing part of the water in this drug targeted supplements (concentrated juices, decoctions, infusions), can be targeted to enrich the drug components to enhance exposure to a particular disease. So, the developers claimed the drug based on it create a spray for the treatment of diseases of the oral cavity and upper respiratory tract by replacing 10-15% water in liquid mumie on vish is the song data for the concentrated juice, which is antiseptic and has otharkivajushchimi and antipyretic properties, and entering the spray essential oil of orange (0,05%) and essential oil of grapefruit (0,03%) as flavourings. In addition, essential oils also have disinfectant and anti-inflammatory actions.

Five taps on the lid of the dispenser (0.15 ml each press) corresponds to 0.75 ml (15 drops). According to scientific medical literature for treatment of inflammatory diseases of the oral cavity, many authors recommend the use of Shilajit topically in the form of smearing, rinse, applications on the mucous membrane, which creates certain inconveniences and difficulties in the application (whether to calculate the concentration and preparation of the solution only 1-2 times use during the day, because the shelf life of aqueous solutions mummy short).

In table 7 the results of comparative trials for the treatment of diseases of the oral cavity tablets mummy and therapeutic drug on the basis of the mummy.

As you can see from the test results, therapeutic effect when used as a therapeutic and prophylactic drug on the basis of Shilajit in most cases surpasses the effectiveness of treatment of disease tablets mummy.

Table 8 presents the results of profilactics what their actions when situations: seasonal exacerbation of chronic gastritis any acidity, weight, complications of diseases associated with endothelial dysfunction (varicose veins, atherosclerosis, metabolic syndrome), osteoporosis.

Table 8
SituationDosage and method of application of the drug on the basis of the mummy
Prevention of seasonal exacerbation of chronic gastritis any acidityIn the complex therapy, course receive 2 times a year (spring, autumn): oral dose of 15 drops 3 times a day (morning, afternoon and evening) for 21 days, 30 minutes before meals. Before use the preparation to pre-dissolve in a volume of 1 tablespoon of boiling water.
Prevention of hypovitaminosisIn the complex therapy, course receive 2 times a year (spring, autumn): oral dose of 15 drops 3 times a day (morning, afternoon and evening) for 21 days, 30 minutes before meals. Before use the preparation to pre-dissolve in a volume of 1 tablespoon boiling water
Prevention of complications of diseases associated with endothelial dysfunction (varicose veins, atherosclerosis, metabolic syndrome, and others) In the complex therapy, course receive 2 times a year (spring, autumn):oral dose of 15 drops 3 times a day (morning, afternoon and evening) for 21 days, 30 minutes before meals. Before use the preparation to pre-dissolve in a volume of 1 tablespoon of boiling water.
Prevention of osteoporosisIn the complex therapy, course receive 2 times a year (spring, autumn): oral dose of 15 drops 3 times a day (morning, afternoon and evening) for 21 days, 30 minutes before meals. Before use the preparation to pre-dissolve in a volume of 1 tablespoon of boiling water.
Prevention of seasonal incidence of SARS and influenzaDuring epidemics oral dose of 15 drops 3 times a day (morning, afternoon and evening) for 21 days, 30 minutes before meals. Before use the preparation
pre-dissolve in a volume of 1 tablespoon of boiled water. When contact with ill add local use: five taps on the cover of the dispenser in the mouth 2 times a day between meals for 10 days.
Prevention of violations of the biocenosis of the oral cavity with prolonged antibiotic therapy.Five of you is on the cover of the dispenser in the mouth 2 times a day between meals for 10 days
Prevention of inflammatory diseases of the oral cavity when wearing dentures30 drops to 12 cups of boiling water to use as a rinse for the mouth 1-2 times a day
Prevention of periodontal disease30 drops to 12 cups of boiling water to use as a rinse for the mouth 1-2 times a day
Prevention of exacerbations of chronic tonsillitisDuring epidemics and in contact with infected: five taps on the cover of the dispenser in the mouth 2 times a day between meals for 10 days

Thus, the claimed therapeutic drug on the basis of Shilajit is convenient in manufacturing and usage dosage form Shilajit with a long shelf life with high quality and high precision dosing when used.

Therapeutic drug on the basis of the mummy, characterized in that it contains purified Shilajit, citrosa grapefruit, glycerin food, ethyl alcohol and water in the following ratio, wt.%:

td align="left"> citrosa grapefruit
Shilajit is cleared25-30
1-6
glycerin food8-10
ethyl alcohol18-22
waterrest



 

Same patents:

FIELD: personal use articles.

SUBSTANCE: invention relates to personal hygiene products that contain multi-layered films with decorative colours and may impart a significant colour change.

EFFECT: invention is applicable to products including typical toothpaste, soaps and other products prior to their dissolution in water (or saliva).

33 cl, 5 tbl, 9 ex

FIELD: personal use articles.

SUBSTANCE: invention relates to personal hygiene products that contain multi-layered films with decorative colours and may impart a significant colour change.

EFFECT: invention is applicable to products including typical toothpaste, soaps and other products prior to their dissolution in water (or saliva).

33 cl, 5 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to composition for oral cavity care and methods of its application. Claimed is composition for oral cavity care, which contains: arginine, in free form or in form of salt in amount from 0.1 to 20 wt % of total composition weight; triclosan in amount from 0.01 to 5 wt % of total composition weight; anionic polymer, which is a copolymer of methyl vinyl ether and maleic anhydrate; anionic surfactant in amount from 0.01 to 10 wt % of total composition weight; soluble fluoride salt in amount from 0.01 to 2 wt % of total body weight, in order to provide 50-25000 ppm of weight of fluoride ions, in which soluble fluoride salt or source of fluoride ions is selected from sodium fluoride, sodium monofluorophosphate and their mixtures; and abrasive material, which contains fraction of minor particles, constituting at least about 5 wt % of total composition weight, and in said fraction minor particles have average diameter d50 smaller than 5 mcm.

EFFECT: application of composition for oral cavity care along with improved delivery of antibacterial agent provides additional advantages in acceleration of remineralisation and restoration of precarious affection foci due to combination of fluoride and arginine, as well as due to application of finely disperse abrasive as composition component.

11 cl, 1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to cosmetology and represents hygienic preparation against foot sweat and smell, placed into hermetic packet from thermally welded material, in whose internal cavity placed are powder-like ingredients of hygienic preparation, placed into containers made from paper with polyethylene coating, or from film combined material, or from three-composite material paper-aluminium foil polyethylene, or from other similar material and manufactured with means of their opening in form of indication of packet opening direction and/or in form of perforation or perforations on the edge or edges of packet, characterised by the fact that is consists of two components: sodium hydrocarbonate and tannin - tannic substance, contained in plant Tamarix, in form of amorphous yellowish shiny powder, each of which is placed into individual package.

EFFECT: invention ensures reduction of sweat-production, increase of bactericidal, disinfecting and deodorising effects, does not induce allergic reactions if applied properly.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new 4-(heterocycloalkyl)benzene-1,3-diol compounds described by general formula (I) presented below, wherein: R1, R2, R3 and R4 may be identical or different, and represent: - hydrogen,- C1-C4-alkyl radical,- hydroxymethyl, hydroxyethyl, - (C1-C4-alkoxy) carbonyl,- C1-C4-alkoxy,- hydroxyl, or R1 and R2 are bound to each other and to a carbon atom whereto attached to form a carbon cycle containing 5 or 6 carbon atoms, while R3 and R4 may be identical or different, and represent: - hydrogen, - C1-C4-alkyl radical, or R1 and R4 are bound to each other to form the chain -(CH2)2- or -(CH2)3-, while R2 and R3 may be identical or different, and represent: - hydrogen, - C1-C4-alkyl radical, X represents an oxygen atom or a sulphur atom, Y represents hydrogen, a chlorine atom or a fluorine atom, the value of m may represent 1 or 2, while the value of n may represent 0 or 1, and provided n=0, then m=1 or 2, and provided n=1, then m=1, as well as to salts of the compounds of general formula (I) and to their isomer and enantiomer forms.

EFFECT: invention relates to the use of these compounds in pharmaceutical or cosmetic compositions for the use in treating or preventing pigmentary disorders.

7 cl, 2 tbl, 19 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I) as well as enantiomers, diastereomers and Z or E isomers thereof, which can be used as an odorising agent or an odour masking agent. In formula (I), R is a hydrogen atom, a methyl group or a methylene group, and in which not more than one of the four dotted lines denotes a carbon-carbon double bond. The invention also relates to methods of producing compounds of formula (I), compositions, including perfume and cosmetic compositions, and a cleaning agent containing said compounds.

EFFECT: novel perfume composition is disclosed.

21 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology, in particular to hair care products. As a hair care product, a hair shampoo is presented which provides improved structure and consistency of the cosmetic product, better tactile sensations, uniform distribution of active substances on the hair and scalp, stable formulation, as well as compatibility with surfactants and electrolytes. The active ingredient is the natural mineral bentonite.

EFFECT: promoted root nutrition, hair growth stimulation; the shampoo prevents hair loss.

1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to cosmetic industry, namely to cosmetic preparation, which contains from 3×10-4 to 1×10-3 wt %, of, at least, one of particular steroids of 16-androstene series, in particular, 4,16-androstadien-3-one and particular steroids of estrene series, as well as from 0.1 to 30 wt % of, at least one film-generating and/or fixing polymer.

EFFECT: claimed cosmetic preparation ensures prevention of unpleasant smell of used steroids in addition to fixation of keratin fibres due to their fixed release due to application of film-generating polymers.

13 cl, 2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to cosmetic industry, namely to cosmetic preparation, which contains from 3×10-4 to 1×10-3 wt %, of, at least, one of particular steroids of 16-androstene series, in particular, 4,16-androstadien-3-one and particular steroids of estrene series, as well as from 0.1 to 30 wt % of, at least one film-generating and/or fixing polymer.

EFFECT: claimed cosmetic preparation ensures prevention of unpleasant smell of used steroids in addition to fixation of keratin fibres due to their fixed release due to application of film-generating polymers.

13 cl, 2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and to methods of their application. Claimed are compositions for oral cavity care, which contain effective amounts of arginine in free or salt form, anionic surface active substance, halogenated diphenyl ether, anionic polymer, and precipitated calcium carbonate, which has d50 from approximately 0.5 to approximately 3 micrometres.

EFFECT: compositions are efficient, in particular, for reduction of bacteria adherence to tooth surface in subject's oral cavity, in addition, chemical composition provides favourable effect in activation of remineralisation, elimination of pre-caries damage and strengthening healthy state of oral cavity along with intensification of taste properties of formulation of preparation for oral cavity care and increase of general acceptability pf product for consumers.

33 cl, 1 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a composition and a combination for treating panniculopathy and problems associated with venous insufficiency of the lower limbs. The composition for treating panniculopathy and problems associated with venous insufficiency of the lower limbs, containing esculoside and at least one compound selected from icarine or its derivatives, or extracts containing it (them), Gingko biloba dimer flavones in a free form or complexed with phospholipids, amentoflavone and at least one compound selected from escin, escin beta sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids, or Centella asiatica extract in a free form or complexed with phospholipids. The use of the combination on the basis of the mentioned ingredients for preparing the composition for treating panniculopathy and problems associated with venous insufficiency of the lower limbs.

EFFECT: above-described composition and combination are effective in reducing panniculopathy and problems associated with venous insufficiency of the lower limbs.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely angiology, intensive care, cardiovascular surgery and phlebology, and may be used for integrated treatment of acute thromboembolia of pulmonary artery. That is ensured by prescribing anticoagulants, disaggregants, antibiotic therapy added by thrombolytic therapy by the oral introduction of the preparation Thrombovasim 0.02 mg/kg combined with deobliteration of pulmonary artery or pulmonary trunk by direct surgical thromboembolectomy in complete bypass with retrograde perfusion of pulmonary arteries. Treatment of acute thromboembolia is added by prescribing the preparation Vasaprostan* 60 mcg daily intravenously starting from the moment of diagnosing and up to 7 postoperative days.

EFFECT: method provides higher clinical effectiveness in the patients and preventing developing complications ensured by correction of main pathological links of developing complications of acute thromboembolia of pulmonary artery.

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is the new chemical compound - a 3-(2,2,2-trimethylhydrazinium)propionate derivative - 3-(2,2,2-trimethylhydrazinium)potassium propionate glycinate, (CH3)3N+NHCH2CH2COOKRCOO-, wherein exhibiting endothelioprotective activity. The presented derivative can find application in medicine in the integrated treatment for endothelial dysfunction correction in cardiovascular diseases.

EFFECT: enhanced endothelioprotective properties as compared with previously known mildronat due to the introduction of new functional group showing the most manifested antioxidant properties.

1 tbl

FIELD: medicine.

SUBSTANCE: there are conducted crossectomy, direct and/or indirect thrombectomy, ligation of inadequate perforating veins and varicose flows of subcutaneous vein stems. A pathological venous bed is eliminated by endovasal laser coagulation (EVLC) of the inadequate subcutaneous vein stems. The surgical procedure is performed under tumescent anaesthesia of the EVLC region by physiologic saline cooled to 6-7°C at ozone concentration 4-5 mcg/ml. It is assisted by continuous ultrasonic navigation. The EVLC region involved in varicothrombophlebitis and the incisional wound are processed by argon-plasma flow followed by elastic compression of the operated extremity.

EFFECT: method extends the range of product for treating acute varicothrombophlebitis of the lower extremities.

FIELD: medicine.

SUBSTANCE: gestosis model in Wistar rats is reproduced by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 14th to 20th day of pregnancy. The simulated pathology is corrected by the subcutaneous introduction of recombinant erythropoietin 50 IU/kg on the 7th, 10th, 13th, 16th, 19th day of pregnancy.

EFFECT: method provides evident placental microcirculation correction.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgery, and may be used for treating acute thrombophlebitis of lower extremities. That is ensured by the subcutaneous introduction of a mixture containing lydase, heparin and novocaine within a first web space of a foot with underlying conventional therapy. It is added with the introduction of a medicated mixture containint 0.25% novocaine 30 ml; lydase 64 standard units; 1% emoxipin 1 ml; dexamethasone 2 ml; fraxiparine 0.6 ml (11400 IU), sodium adenoside-triphosphate 1 ml; cefotaxime 1 mg; nicotinic acid 2 ml into a dorsal and plantar direction, to a medial and lateral side from the Achilles tendon, as well as around a vein involvement wherein a pathological process of acute thrombophlebitis develops, and into interspinous ligaments of the L2-3-L3-4 lumbar vertebrae. The therapeutic sessions are performed every second day within a therapeutic course of 5-10 procedures to arrest the inflammatory process completely. The therapeutic course is applied once more in 2-3 months.

EFFECT: method provides higher clinical effectiveness, reduced risk of threatening complications and limited progression of the disease due to pathogenetically proved action of surface and deep lymphatic networks of the lower extremities with expected activation of the transcapillary exchange.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely restorative medicine and angiology, and may be used for treating the patients with chronic lymphovenous insufficiency of lower extremities. That is ensured by applying a homogenised gel of brown algae at temperature 28-30°C and wrapping the extremities with non-woven tissues (drapes). That is followed by immediate alternative pneumatic compression by the Lympha-E apparatus on the lower extremities. That involves the ascending wave pressure memorising mode, the II operation mode at pressure 60-90 mm Hg for 40-60 minutes. The procedures are daily, 5 times a week with a pause of 2 days. The therapeutic course is 10-20 procedures.

EFFECT: method provides higher clinical effectiveness at all the stages in any length of the disease including due to additional stimulation of the lymphodrainage function, improved microcirculation, peripheral haemodynamics, improved plasma-coagulation phase of haemostasis, improved tissue trophism.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgery, and may be used for sclerosing therapy of hemorrhoid. That is ensured by the sclerosing therapy by introducing a detergent into a hemorrhoid. It is immediately followed by a vibroacoustic session above the sclerosed hemorrhoids. The vibroacoustic session is performed in the frequency range of 0.26 kHz and 0.55 kHz alternatively 30 sec each for 3 minutes.

EFFECT: method provides higher clinical effectiveness ensured by faster relief of the perianal inflammation manifestations, reduced complications and recurrences after a single action of sclerosants.

3 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. Group of inventions involves the use of lisuride or terguride or their enantiomers, or their salts or hydrates for treating and preventing pulmonary arterial hypertension, endogenic or exogenic induced glomerular sclerosis, as well as secondary Reynaud's syndrome; the use of lisuride or terguride or their enantiomers, or their salts or hydrates for treating and preventing said diseases; a pharmaceutical composition for treating and preventing said diseases containing a compound specified in a group consisting of lisuride, terguride, their enantiomers, as well as their salts or hydrates, together with a pharmaceutically compatible carriers, excipients and/or solvents.

EFFECT: group of inventions provides higher therapeutic and preventive effectiveness.

6 cl, 10 ex, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves simulating gestosis in Wistar rats by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 14th to 20th day of pregnancy. The simulated pathology is corrected by the subcutaneous introduction of recombinant erythropoietin 50 IU/kg on the 7th, 10th, 13th, 16th, 19th day of pregnancy.

EFFECT: method provides correction of systemic endothelial dysfunction accompanying gestosis in the specific experimental environment.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at treating acute and aggravated chronic laryngitis. What is involved is specific antibioticotherapy per os with additional examination of microflora starting from the 3rd-5th day of the therapy followed by instillations of specific, result-related bacteriophagues into the larynx in the amount of 0.5-1.0 ml in acute laryngitis for 7-10 days, and in aggravations for 10-14 days.

EFFECT: method provides higher clinical effectiveness ensured by a lower number of side effects and complications, and a reduced length of treatment.

16 tbl, 2 ex

Up!